Jordi Galván

567 total citations
35 papers, 386 citations indexed

About

Jordi Galván is a scholar working on Immunology, Dermatology and Surgery. According to data from OpenAlex, Jordi Galván has authored 35 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 9 papers in Dermatology and 8 papers in Surgery. Recurrent topics in Jordi Galván's work include Psoriasis: Treatment and Pathogenesis (8 papers), Dermatology and Skin Diseases (7 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Jordi Galván is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (8 papers), Dermatology and Skin Diseases (7 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Jordi Galván collaborates with scholars based in Spain, Germany and United Kingdom. Jordi Galván's co-authors include John Slof, Ricardo Díez Valle, Camila Arza, Ulrike Blume‐Peytavi, Veronica Tebbs, Carlos Vila, M. Falqués, Bianca Maria Piraccini, Remedios Otero and Miguel J. A. Láinez and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Journal of Neurology and Journal of Clinical Medicine.

In The Last Decade

Jordi Galván

30 papers receiving 365 citations

Peers

Jordi Galván
Jung Hyun Shin South Korea
Mansooreh Bagheri Iran
Anca Cardoneanu Romania
Neil Badlani United States
Kyoichi Obata Japan
Hung‐Jen Wang Taiwan
Liangwan Chen China
Darcy L. DiFede United States
Alessandra Menon Italy
Jung Hyun Shin South Korea
Jordi Galván
Citations per year, relative to Jordi Galván Jordi Galván (= 1×) peers Jung Hyun Shin

Countries citing papers authored by Jordi Galván

Since Specialization
Citations

This map shows the geographic impact of Jordi Galván's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordi Galván with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordi Galván more than expected).

Fields of papers citing papers by Jordi Galván

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordi Galván. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordi Galván. The network helps show where Jordi Galván may publish in the future.

Co-authorship network of co-authors of Jordi Galván

This figure shows the co-authorship network connecting the top 25 collaborators of Jordi Galván. A scholar is included among the top collaborators of Jordi Galván based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordi Galván. Jordi Galván is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galván, Jordi, et al.. (2024). CONTACT ANAPHYLAXIS TO TOPICAL DICLOFENAC: A CASE REPORT.. Annals of Allergy Asthma & Immunology. 133(6). S106–S106.
2.
Bewley, Anthony, et al.. (2024). Burden of Topical Treatments in Psoriasis and Preferred Criteria of Choice: A Survey-Based Evaluation of Patients in Europe. Dermatology and Therapy. 14(6). 1497–1514. 1 indexed citations
3.
4.
Torres, Tiago, Jordi Galván, Lars Iversen, et al.. (2023). Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review. Dermatology and Therapy. 13(10). 2153–2169. 3 indexed citations
5.
Galván, Jordi, et al.. (2023). A RARE CASE OF TOXIC EPIDERMAL NECROLYSIS ASSOCIATED WITH THE USE OF VANCOMYCIN. CASE REPORT. Annals of Allergy Asthma & Immunology. 131(5). S100–S100.
6.
7.
Pinter, Andreas, Linda Stein Gold, Adam Reich, et al.. (2022). A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30thEADV Congress 2021. Journal of the European Academy of Dermatology and Venereology. 37(S1). 14–19. 4 indexed citations
8.
Piraccini, Bianca Maria, Ulrike Blume‐Peytavi, M. Falqués, et al.. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286–294. 75 indexed citations
9.
Galván, Jordi, et al.. (2015). El valor de la oxibutinina en parche transdérmico en el tratamiento de la vejiga hiperactiva. Actas Urológicas Españolas. 39(10). 599–604. 8 indexed citations
10.
Slof, John, Ricardo Díez Valle, & Jordi Galván. (2015). Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery. SHILAP Revista de lepidopterología. 30(3). 163–168. 34 indexed citations
11.
Slof, John, Ricardo Díez Valle, & Jordi Galván. (2014). Análisis coste-efectividad de la cirugía del glioma maligno guiada por fluorescencia con ácido 5-aminolevulínico. Neurología. 30(3). 163–168. 32 indexed citations
12.
13.
Tornero, Carlos, et al.. (2012). Buprenorfina transdérmica (Feliben®): Nueva opción terapéutica para pacientes con dolor moderado y severo. Revista de la Sociedad Española del Dolor. 19(6). 301–309.
14.
Crespo, Carlos, Max Brosa, Jordi Galván, et al.. (2010). Análisis farmacoeconómico de Metoject® en el tratamiento de la artritis reumatoide en España. Reumatología Clínica. 6(4). 203–211. 7 indexed citations
15.
Blanco, Francisco J., Javier Ballina, Jordi Carbonell, et al.. (2010). Estudio descriptivo de la utilización de los FAMES en los pacientes con artritis reumatoide o artritis persistente que inician tratamiento farmacológico en España. (ESTUDIO FIRST). Reumatología Clínica. 7(2). 88–93. 10 indexed citations
16.
Galván, Jordi. (2009). Estudio coste-efectividad de leflunomida frente a metotrexato. Reumatología Clínica. 5(6). 291–292. 2 indexed citations
17.
Láinez, Miguel J. A., et al.. (2007). Crossover, double‐blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. European Journal of Neurology. 14(3). 269–275. 26 indexed citations
18.
Argila, Carlos Martín de, et al.. (2007). Acceptability of Lansoprazole Orally Disintegrating Tablets in Patients with Gastro-Oesophageal Reflux Disease. Clinical Drug Investigation. 27(11). 765–770. 8 indexed citations
19.
Slof, John, et al.. (2005). Cost-efficacy of oral triptans in the treatment of acute migraine. Journal of Medical Economics. 8(1-4). 27–43. 3 indexed citations
20.
Pascual, Jose Leonard R., et al.. (2003). [Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study].. PubMed. 18(1). 7–17. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jung Hyun Shin Breakdown of academic impact, for papers by Mansooreh Bagheri Breakdown of academic impact, for papers by Anca Cardoneanu Breakdown of academic impact, for papers by Neil Badlani Breakdown of academic impact, for papers by Kyoichi Obata Breakdown of academic impact, for papers by Hung‐Jen Wang Breakdown of academic impact, for papers by Liangwan Chen Breakdown of academic impact, for papers by Darcy L. DiFede Breakdown of academic impact, for papers by Alessandra Menon
Rankless by CCL
2026